Krishnan Ramanathan

Fabulous to be on the investor panel for Mintz’s Life Sciences Pitch Event today, on yet another glorious fall day in Boston. ☀️🍁 (Although perhaps all meetings that start at 8am should come with good weather?) Key feedback shared by our panel: 🔹 Ensure your target market is clear - especially when the population for your relevant indication is highly heterogenous 🔹 Share your current assumptions about how your product may be used (e.g., chronically vs. episodically) and open questions 🔹 If you're exploring a range of commercial use cases, share how you anticipate prioritizing across them over time 🔹 If your GTM strategy requires you to displace heavily entrenched solutions and/or processes, share how you will enable these transitions 🔹 Note the specific set of milestones to be achieved with investment 🔹 Always include target timelines and potential paths to exit Thank you to the incredible lineup of entrepreneurs who pitched today, and please stay in touch! Thank you to Dean Farmer and Charlie C. for facilitating today's event. Thank you to panelists David Fogel, CPA, Ben Littauer (he/him), Molly Hoult, and Richard Wagner for your contributions. Great to meet you, and thank you for all of your help, Emily (Krasowski) Yanachkov and Diana Malkin. #lifesciences #pitchevent #investor #panel #boston

86

4 Comments

How do we minimize the number of protocol amendments and increase the operational feasibility of our clinical trials? This article below points out the benefits of using data, conversations and real world data to enhance the feasibility of the protocol design and inclusion/exclusion criteria: 1) Are we being too strict on our criteria in order to "control" for data variability? 2) Do are criteria allow for the intended patient population in the real world (if not, they need to) 3) How realistic is your design in how the study sites actually work? How they see and treat patients? How is your company ensuring the design meets these requirements? https://lnkd.in/gzJzFd-3

4

1 Comment

Can one question drive a professional career full of commercial success? For Mike Rea of IDEA Pharma | From R&D to RxD, the question for pharmaceutical companies assessing new molecules has been: "If you gave the same molecule to two different companies in phase I, would they be equally successful?" Intuitively, not all companies will achieve the same success if given the same opportunity. I’ve found a lot of value in the 13-year benchmark survey: the Idea Pharma Innovation and Invention Index tracking the top-performing pharmaceutical companies by sales. https://lnkd.in/gwX554WM In the benchmark survey (link below), Mike and his team track invention and innovation capabilities and apply the lessons they have learned to help pharmaceutical companies deliver 8 out of the top 15 product launches from 2015 to 2020. While Mike’s research focuses on pharma, there are ample lessons that are industry-agnostic. Please join me on Thursday, June 20th, at 7 AM Pacific / 4 PM CET in the 4x4 Innovation Group, where I will interview Mike Rea. https://lnkd.in/gxDGv4dB In our discussion, we will cover: - The role consistency plays in innovation - Finding value where consensus suggests there is none - Invention vs. Innovation in pharma - What can pharma teach us about innovation more broadly For more on Mike: https://lnkd.in/gpswDr24 More on Idea Pharma: https://lnkd.in/gXTSZWvf #innovationmanagement #positioning #pharma

16

6 Comments

AbbVie has lost >$45B in market capitalization since the negative Phase II readouts on emraclidine, the schizophrenia drug they acquired via their $8.7B buyout of Cerevel Therapeutics. Competing neuropsychiatric drug developers Neumora and Neurocrine Biosciences have faced similar setbacks on their schizophrenia drugs leaving only Bristol Myers Squibb's Cobenfy (acquired via their buyout of Karuna Therapeutics for $14B in cash) and Terran Biosciences' TerXT the only real assets of significant value and with near-term hopes for commercialization. Given TerXT's superior release profile (once-daily oral pill vs. Cobenfy's twice daily regimen) along with a long-acting injectable form that could last up to six months, as well as TerXT's reduced side effects, analysts are speculating that TerXT could take substantial market share from Cobenfy which is projected to reach as much as $10B in annual sales. This all adds up to TerXT being exceptionally well positioned in a white hot neuropsychiatric biopharma M&A market.

25

3 Comments

Must-watch TEDx talk by Sheila Gujrathi, MD “ Focus on the Mirror, Not the Glass Ceiling.” As an accomplished biotech leader, Sheila shares her powerful insights on diversity, belonging, and thriving in executive and board roles. Her story of overcoming barriers is inspiring, and her advocacy for inclusivity in leadership is a reminder that we all belong in the rooms we enter. A must-see for those looking to foster more diverse, equitable workplaces. https://lnkd.in/eC5MyRpp

29

1 Comment

Legend Biotech, a CAR-T specialist, has reportedly received a takeover bid and hired Centerview Partners to evaluate options. The news led to a 12% increase in Legend's stock on Nasdaq and a 25% rise in GenScript's stock in Hong Kong. Known for its collaboration with Johnson & Johnson on the CAR-T therapy Carvykti, Legend might be a potential acquisition target for J&J. This comes amid a biosecurity crackdown on Chinese biopharma firms, possibly motivating J&J to mitigate risks by taking control of Legend. Click here to read more: https://bit.ly/3Y79uhM #CAR-T #M&A, #venturecapital #privateequity #deerbornedifference

5

This week, Mark Campbell, RxBenefits, Inc.'s Chief Pharmacy Officer shared his perspective on the way drug manufacturers, formulary practices by the leading pharmacy benefit managers, and the economics of rebates have led to patients, plan sponsors, and our healthcare system missing out on the significant savings #biosimilars could have delivered. Great insights and lessons we can learn for the future

10

Takeda's CEO's annual letter hits on some key themes that many biopharma CEO's are converging on: value-based care, price transparency, breaking up the middlemen, and driving healthcare access and equity. "For several years I have been outlining Takeda’s thinking on health equity—including advocating for a transition to value-based health care that pays for outcomes and care quality, emphasizing the need to prepare for the next pandemic by ensuring global vaccine equity and explaining how the protection of intellectual property rights is essential to incentivize investment in R&D. One area where we would like to see greater progress this year is pharmacy benefit managers reform. We support efforts in Congress to delink rebates from list prices or wholesale acquisition cost. It is a complex system, but the bottom line is that the current system creates misaligned incentives that ultimately result in higher costs for the system and higher out-of-pocket costs for patients. One potential way to address these challenges is through greater transparency. Transparency at the point of purchase for patients would empower them to make decisions knowing exactly what their costs will be. This could lower costs for the entire system by building in greater pricing accountability along the chain so that no stakeholder can benefit from the inefficiencies that result in the prices that patients pay today." At COEUS, we are working with the world's leading biopharma companies to help transition them from a broken FFS model towards value-based care. We have built the world's leading platform that hosts the biggest CGT commercial launches, and rapidly moving into Oncology, Obesity/ Diabetes, and beyond. 1. Enabling Value-Based Healthcare: Our solution facilitates the transition to value-based healthcare by providing a powerful tool for creating and managing contracts that pay for outcomes and care quality. 2. Enhancing Transparency: By aggregating disparate healthcare data from various sources, our platform provides unprecedented transparency into the entire healthcare ecosystem. This empowers payers, providers, and patients to make informed decisions and helps stakeholders across the value-chain to tie price and value to therapeutic outcomes. 3. Driving Innovation: Our platform's ability to evaluate complex rules for value-based contracts, real-world evidence studies, and health equity measurements fosters innovation in the pharmaceutical industry. By providing a tool to measure the impact of new solutions, we help companies drive medical advancements while ensuring equitable access. 4. Improving Access and Affordability: Our solution helps identify areas where access and affordability can be improved without compromising innovation. By providing data-driven insights into the effectiveness of various interventions, we enable stakeholders to make informed decisions that benefit patients and the healthcare system as a whole. Visit https://coebra.ai/.

10

All pharma CEOs need to understand that they have a responsibility beyond that to their shareholders. Maximizing profits for shareholders beyond what is needed to earn a return on R&D investment—at the expense of people who cannot afford their pharmaceuticals—is unethical. Business ethics should be taught not only in MBA school, but in all undergraduate and graduate programs.

5

2 Comments

🌟 Advancing ADCs: Latest weekly updates from the industry Exciting regulatory milestones in the world of ADCs! 🏅 Mabwell innovative Nectin-4-targeting ADC, 9MW2821, secured FDA Fast Track Designation for treating Nectin-4 positive TNBC. Additionally, it earned FTD for ESCC, CC, and Orphan Drug Designation for EC. 🏷 In China, Mabwell continues to make strides with NMPA approval for Phase II trials of 9MW2821 in TNBC, boasting a promising 50.0% ORR and 80.0% DCR in early results. 🏅 Mabwell's 7MW3711, a B7-H3-targeting ADC, received Orphan Drug Designation for SCLC, showcasing potent tumor-killing effects and a positive safety profile. 🤝 In deals and collaborations, SOTIO partners with Biocytogen to expand its ADC pipeline with fully human bispecific antibodies, potentially receiving milestone payments up to $325.5 million. 🤝 Sanyou Biopharmaceuticals and Huadong Medicine join forces to develop the ADC program SYHD001, now in Phase I clinical trials. Follow for more updates and expert insights. Stay informed, stay competitive! #ADCs #Biopharma #RegulatoryUpdates #Pharmaceuticals

13

How far can good leaders progress a drug that has bad data? That was the question posed to Sonal Kothari-Gupta, MD, PhD Gupta, the SVP Clinical Development at AffyImmune Therapeutics. We discuss the effects bad leadership has on good science. However I wanted to know what good leaders do when they have bad data. Is there such a thing as a good leader who progresses bad data? Sonal discusses this point and why having good leadership at the top is essential for a companys clinical (and ethical) strategy. —--- Podcast access:  👉 Podcast access: Search "Bad Science vs. Good Leadership in Biotech Charles Spence” on spotify, apple etc.  👉 For career talks, industry trends and more - search “Dose of Reality Charles Spence” in your favourite podcast platform.

37

3 Comments

I sat down with Fierce Pharma to share insights into the recent flurry of #biopharma acquisitions and the strategic considerations behind them. While large-scale deals dominate headlines there are many advantages for smaller, targeted acquisitions for long-term shareholder returns. These strategic moves provide an opportunity to mitigate risks and foster innovation, particularly in cutting-edge areas like #cellandgenetherapy. Smaller acquisitions may have potential to drive innovation that can help expand your market reach into new modalities and put you on the leading edge of science in front of your competition. By prioritizing talent retention and leveraging clinical data, companies can position themselves for sustained growth and leadership in the competitive #biotech sector. 

69

2 Comments

Under the leadership of Ron Alfa, MD, PhD, NOETIK is pushing the boundaries of AI-driven precision cancer therapies. Noetik’s recent $40 million Series A financing will further their mission to leverage machine learning for personalized medicine, reflecting a broader industry trend where AI is revolutionizing drug discovery and patient care. As AI continues to evolve, its role in transforming healthcare becomes even more critical, setting new standards for innovation and patient outcomes. Polaris Partners Khosla Ventures Breakout Ventures Wittington Ventures Zetta Venture Partners Catalio Capital Management 11.2 Capital EPIC Ventures ApSTAT Technologies Linearis @Ventures Platform Fund Yoshua Bengio David S. Wishart Jean-François Gagné Shafique Virani, MD FRCS James Hardiman #innovation #AI #Biotechnology #AIinhealthcare

28

1 Comment

🧓👵👴Long-Term Care Gets a Tech Boost: How New Advancements Benefit Seniors and Pharmacists? Here at TIB Pharmacy, we're passionate about empowering our patients to live healthy, independent lives. That's why I'm thrilled about the recent surge in technology designed to support seniors in long-term care facilities and even at home. As your pharmacist, I've seen firsthand how these advancements can benefit patients: **Improved Medication Adherence: Medication reminders and easy video calls with caregivers can significantly improve medication adherence, reducing complications and potentially lowering the need for additional prescriptions. **Early Detection of Health Concerns: Wearable health trackers can monitor vitals and activity levels, allowing for earlier detection of potential health issues. This means faster intervention and potentially fewer medication adjustments due to missed symptoms. **Promoting Independence: Technology like GPS trackers and video calls empowers seniors to manage their daily lives at home, reducing feelings of isolation and potentially decreasing the need for certain medications used to manage those conditions. Here's how I can help: **Educating Patients and Families: I'm happy to discuss these advancements with you and your loved ones, exploring how they can improve well-being and potentially reduce medication-related issues. **Partnering with LTC Facilities: Collaboration with LTC facilities ensures residents receive the medications they need while seamlessly integrating these new technologies. **Staying Current on the Latest Tech: The world of senior care technology is constantly evolving. I'm committed to staying up-to-date to best serve my patients. Technology is transforming long-term care, and at TIB Pharmacy, we're excited to be part of it. Let's work together to create a future where seniors can enjoy a higher quality of life with greater independence and better health outcomes. Let us know your thoughts about this, feel free to share it in the comments section! Call us! TIB Pharmacy T: (510)-573-0064 A: 5886 Mowry School Rd, Newark CA, 94560 #LongTermCare #MedicationManagement #BetterHealth #Teamwork #TIBPharmacy #NewarkPharmacy #pharmacyservices #longtermcare #LTCPharmacy #HospicePharmacy #EndOfLifeCare #hospicespecialized #ltcspecialized #ltcathome #enteraltherapy #MedicationManagement #PackagingPower #SimplifyYourHealth https://lnkd.in/gUWj3PGp

3

1 Comment

🔊 Stay ahead with latest updates on ADC in Oncology Exhibit #1: News by different category and phase of development Exhibit #2: A key recent update with insights 🔬 Immunome, Inc.’s IM-1021 (ROR1 ADC) demonstrates superior preclinical efficacy against zilovertamab vedotin in MCL and TNBC models, along with enhanced ADME properties over deruxtecan. IND filing expected Q1 2025. 🧪 Daiichi Sankyo US Sankyo and AstraZeneca initiate dosing in three global Phase 3 trials—TROPION-Lung10, TROPION-Lung14, and TROPION-Lung15—testing Datopotamab Deruxtecan (TROP2 ADC) combinations in advanced/metastatic non-squamous NSCLC. 🧪 Sutro Biopharma, Inc. Biopharma begins enrolling in the REFRαME-P1 trial to assess luvelta (FRα ADC) for pediatric patients with CBF/GLIS AML. 🎯 Hansoh Bio’s HS-20093 (B7-H3 ADC) receives Breakthrough Therapy Designation from NMPA for extensive-stage SCLC treatment. 🎯 Kelun-Biotech's NDA for sacituzumab tirumotecan (TROP2 ADC) accepted by NMPA for EGFR-mutant NSCLC, after Phase 3 OptiTROP-Lung04 results showed notable PFS improvement. 💡 Crescent Biopharma acquires GlycoMimetics, expanding its pipeline with novel ADCs CR-002 and CR-003. 🏗️ MilliporeSigma invests $76M to expand ADC manufacturing by 34,000 sq. ft. in St. Louis, adding 170 jobs and solidifying its position as North America's first approved ADC CDMO. 🤝 Ryvu Therapeutics and nCage Therapeutics partner to advance ADCs using TRAP cage technology for improved efficacy and safety. 💰 Sterling Pharma Solutions allocates £10M to double GMP bio-conjugation capacity at its UK site for ADC development. 💰 CrossBridge Bio secures $10M in seed funding led by TMC Venture Fund and CE-Ventures to advance CBB-120 (TROP-2 ADC) and expand its ADC pipeline. 🤝 Lonza’s Synaffix licenses ADC technology to BigHat Biosciences, combining ADC and AI-driven antibody design to enhance its ADC pipeline. 📅 Sutro Biopharma, Inc. will present five sessions on its cutting-edge ADCs at the 15th Annual World ADC Conference in San Diego, November 4-6, 2024.

43

Great summary and insight! Starting early is key to developing the critical partnerships needed for a successful launch.

7

🧬 Big Pharma's Facing a Tidal Shift 🚀 As Humira's monopoly fades into history, it's ushering in an era of biologic competition - and that's just the tip of the iceberg. We're looking at industry titans on the brink of a patent cliff, preparing to dive into uncharted waters with drugs for obesity and Alzheimer's. 🌊 Leaders, consider this: the Inflation Reduction Act might shake up the game, but innovation never sleeps. It's time for strategic pivots - novel therapies, smarter operations, and yes, a marketing revamp. 💡 To my fellow execs in MedTech & HealthTech, we have pivotal roles here. Let's navigate these changing tides together, leveraging expertise & forward-thinking to thrive in this next-gen biopharma landscape. 🚀 #Biotech #Innovation #PharmaceuticalIndustry

1

“This is how it has always been done” or “This is how everyone does it” are no longer sufficient. We have to be creative and take risks to disrupt the status quo and forge new paths. #healthcare #clinicaltrials #raredisease

13

2 Comments

Coming soon to Podcast Channel near you. Check out the YouTube Channel and save your spot by being one of the first to subscribe. First episode to air soon!!!! https://lnkd.in/gNyu_aip #decodinghealth #science #knowledge

6